{
    "organizations": [],
    "uuid": "acca97da0af9605b6b4b16045d23569569cfe1a1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1SA1AK",
    "ord_in_thread": 0,
    "title": "Cellectis Submits Investigational New Drug Application To FDA For UCART22",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - CELLECTIS SA:\n* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22\n* UCART22 IS CO’S SECOND WHOLLY CONTROLLED TALEN® GENE-EDITED PRODUCT CANDIDATE FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN ADULT PATIENTS\n* PENDING REGULATORY CLEARANCE, CELLECTIS PLANS TO INITIATE A PHASE I CLINICAL TRIAL IN Q3 2018\nSource text for Eikon:\n (Gdynia Newsroom)\nOur ",
    "published": "2018-05-03T14:11:00.000+03:00",
    "crawled": "2018-05-04T16:33:55.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cellectis",
        "sa",
        "said",
        "wednesday",
        "submitted",
        "investigational",
        "new",
        "drug",
        "ind",
        "application",
        "u",
        "fda",
        "requesting",
        "approval",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "ucart22",
        "ucart22",
        "co",
        "second",
        "wholly",
        "controlled",
        "product",
        "candidate",
        "treatment",
        "acute",
        "lymphoblastic",
        "leukemia",
        "adult",
        "patient",
        "pending",
        "regulatory",
        "clearance",
        "cellectis",
        "plan",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "q3",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}